Summary
- Fusilev delivered opportunistic growth for Spectrum but earnings are now dependent on the six approved cancer drugs.
- Despite lackluster sales, approved therapeutics generate meaningful incomes to fund further innovation.
- Developing molecules (poziotinib and Rolontis) are likely to post positive data (and to deliver significant sales).
During the 2009 to 2012 leucovorin shortage, shares of Spectrum Pharmaceuticals (NASDAQ:SPPI) (a firm that focuses on the development and commercialization of drugs to treat blood disorders and cancers) soared from $5 to $17 peak. The company's lead drug, Fusilev, a pure racemic form of leucovorin, is used as a folate analog for methotrexate rescue therapy. It is also indicated in combinations with 5-fluorouracil for the palliative management of advanced metastatic colorectal cancer.
To learn more how Dr. Tran BioSci can serve your specific needs ...
If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.
